升主动脉瘤患者中的不对称二甲基精氨酸
Asymmetric Dimethylarginine in Patients with Ascending Aortic Aneurysms.
作者信息
Gavriliuk Natalia D, Druzhkova Tatiana A, Irtyuga Olga B, Zhloba Alexandr A, Subbotina Tatiana F, Uspenskiy Vladimir E, Alexeyeva Nina P, Moiseeva Olga M
机构信息
Department of Heart and Vessels Research, Federal Almazov North-West Medical Research Centre, St. Petersburg, Russia.
Department of Biochemistry, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia.
出版信息
Aorta (Stamford). 2016 Dec 1;4(6):219-225. doi: 10.12945/j.aorta.2016.16.025. eCollection 2016 Dec.
BACKGROUND
Ascending thoracic aortic aneurysm (aTAA) is a heterogeneous group of disorders that involve impaired endothelial function. The nitric oxide (NO) synthase inhibitor asymmetric dimethylarginine (ADMA) serves as an endothelial dysfunction marker. Thus, we investigated ADMA levels in patients with aTAA.
METHODS
Eighty-six patients with aTAA and 18 healthy individuals were enrolled. All patients underwent echocardiography. Plasma ADMA levels were measured using high-performance liquid chromatography.
RESULTS
ADMA levels were higher in aTAA patients than in control patients (p = 0.034). According to the multivariable regression model, higher ADMA levels were associated with ascending aortic diameter (p = 0.017), smoking (p = 0.016), and log-transformed estimated glomerular filtration rate (eGFR, p = 0.005).
CONCLUSION
This pilot study demonstrates an association of ADMA with ascending aortic dilatation; however, further studies are needed to investigate whether increased ADMA levels underlie aTAA development.
背景
升主动脉瘤（aTAA）是一组异质性疾病，涉及内皮功能受损。一氧化氮（NO）合酶抑制剂不对称二甲基精氨酸（ADMA）作为内皮功能障碍标志物。因此，我们研究了aTAA患者的ADMA水平。
方法
纳入86例aTAA患者和18名健康个体。所有患者均接受超声心动图检查。采用高效液相色谱法测定血浆ADMA水平。
结果
aTAA患者的ADMA水平高于对照患者（p = 0.034）。根据多变量回归模型，较高的ADMA水平与升主动脉直径（p = 0.017）、吸烟（p = 0.016）和对数转换后的估计肾小球滤过率（eGFR，p = 0.005）相关。
结论
这项初步研究表明ADMA与升主动脉扩张有关；然而，需要进一步研究以调查ADMA水平升高是否是aTAA发生的基础。
Zotero 插件